Spoken Alpha
OnKure Therapeutics, Inc.
OnKure Therapeutics develops precision cancer medicines using structure-based drug design to selectively target specific mutations in PI3Kα, particularly the H1047R variant found in breast cancer.
OnKure Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $101.2M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-10-04.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add OKUR, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OKUR.
$ curl https://api.spokenalpha.com/v1/companies/OKURFAQ
Spoken Alpha indexes OKUR's earnings call transcripts at https://spokenalpha.com/companies/OKUR. Each call links to attributed speakers and parsed analyst Q&A. OnKure Therapeutics, Inc.'s own investor relations page is at https://onkuretherapeutics.com/investors.
OnKure Therapeutics, Inc. (OKUR) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.35 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-03 | $-0.31 | $-0.58 | +46.6% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $-1.11 | $-0.74 | -50.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-12 | $-0.99 | $-1.15 | +14.1% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-1.09 | $-1.20 | +9.2% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-1.14 | $-1.25 | +8.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-1.19 | $-1.38 | +14.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-09 | $-1.37 | $-0.87 | -57.5% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.86 | $-0.90 | +4.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-1.60 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-2.52 | — | — | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-7.05 | — | — | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-5.68 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-6.46 | — | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-6.03 | — | — | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-26 | $-5.54 | — | — | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-5.31 | — | — | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-5.03 | — | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-5.33 | — | — | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-4.34 | — | — | — | — | — | EODHD |
Source: EODHD. OKUR reported actuals as published; sparse fields render as —.